5 results about "Nucleosome" patented technology

Provided herein are improved methods and systems and systems for analyzing cfNA, including improved methods and systems for fragmentomics and their various applications. The methods and systems described herein can be used for assessing gene expression or replication, disease diagnosis, and evaluating immune responses.

To provide compositions and methods for increasing efficiency of targeted genome / epigenetic modification in eukaryotic cells.SOLUTION: A fusion protein comprises at least one nucleosome interacting protein domain linked to a programmable DNA modification protein. A method for increasing efficiency of targeted genome or epigenetic modification in an eukaryotic cell comprises introducing, into the eukaryotic cell, the fusion protein or a nucleic acid encoding the fusion protein.SELECTED DRAWING: None

The application discloses a cancer risk assessment model based on low-depth free DNA sequencing data and application thereof. The marker acquisition method of the cancer risk assessment model comprises the following steps: filtering free DNA sequencing data of a subject sample to obtain free DNA gene mutation data; then, at least one of gene mutation map data, mutation site proportion in regulatory subunit data, length distribution data of free DNA, broken end base distribution data of free DNA, and end distribution data of free DNA in nucleosomes of the subject is acquired according to the free DNA gene mutation data, and is used as the cancer risk prediction marker. The risk assessment model constructed by using the cancer risk prediction marker disclosed by the application has good diagnosis accuracy and wide applicability, and can be used for cancer risk assessment.

The present invention relates to methods for determining the concentration of cell-free DNA (cfDNA) from capillary electropherogram and calculating the proportion of short fragments from mono-nucleosomes. In some embodiments, the determination of cfDNA concentration and mono-nucleosome short fragment proportion, optionally in combination with a panel of screened protein biomarkers, can be used to achieve efficient and cost-effective early detection of multiple cancer types.

The invention relates to methods for quantifying the amount of a nucleosome or a histone associated with a nucleosome in a biological sample wherein the method is calibrated using a nucleosome reference standard in a pre-calibration step.